Medical Tech & Biotech: A Northern China study links early-onset type 2 diabetes (diagnosed before 40) to a heavier burden of kidney, eye, and heart complications than later-onset disease. Oncology Trial: Glutamine is being added to gemcitabine plus nab-paclitaxel in a phase 1 trial for advanced pancreatic cancer, with researchers reporting safety and a recommended phase 2 dose. Next-Gen Memory Hardware: A Singapore team reports chip-scale picosecond magnetic switching using picosecond plasma pulses, aiming to slash write energy for magnetic memory. AI for Science: IRIS reconstructs individual-cell signaling histories from single-cell data, moving beyond “snapshot” gene expression. Robotics Vision: A new RGB-thermal tracker targets performance in darkness and clutter by fusing visible and thermal sensing. Energy Materials: Nickel’s alkaline water-splitting surface chemistry is mapped species-by-species to guide cheaper, more efficient electrolyzers. AI Governance & Security: OpenAI’s Navier-Stokes claim sparks a credit-and-trust fight, while Anthropic says it blocked misuse of Claude for cyber and chemical/bioweapons-related work. Policy & Regulation: The RBI rejected Tata Sons’ deregistration bid, setting up a mandatory listing path; the UK’s nutrition advisory panel faces renewed scrutiny over industry ties. Open Source: Void Linux bans undisclosed AI-generated code in core repositories, requiring disclosure and human review.